(Q34588722)

3 August 2017

1 reference

title

Rasburicase: a potent uricolytic agent (English)

1 reference

3 August 2017

Ching-Hon Pui

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

Expert Opinion on Pharmacotherapy

3 August 2017

published in

1 reference

3 August 2017

volume

3

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

433-442

1 reference

Urate oxidase: primary structure and evolutionary implications

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.4.433

Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.4.433

Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.4.433

Metabolic studies of allopurinol, an inhibitor of xanthine oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.4.433

Development of a two-site immunoassay of recombinant urate oxidase (SR 29142) and its use for determination of pharmacokinetic parameters in rats and baboons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.4.433

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.4.433

Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.4.433

The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.4.433

21 January 2018

Identifiers

DOI

10.1517/14656566.3.4.433

1 reference

3 August 2017

1 reference